You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

633 Results
Document
New
Jul 2025
Document
New
Jul 2025
Document
New
Jul 2025
Document
New
Jul 2025
The Indigenous Palliative Care Fact Sheets are developed to support First Nations, Inuit, Métis and urban Indigenous people living with a life-...
Document
New
Jul 2025
Drug
Other Name(s): Imbruvica®
Quick Link(s): Drug Monograph, Patient Info Sheet
Dec 1969
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    iBRUtinib - For the treatment of patients with chronic lymphocytic leukemia (CLL), in combination with venetoclax, based on criteria
Exceptional Access Program
    venetoclax - For the treatment of patients with chronic lymphocytic leukemia (CLL), in combination with ibrutinib, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
iBRUtinib,
venetoclax
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
The Provincial Drug Reimbursement Programs (PDRP) administers funding programs for cancer drugs and services. These programs help patients access...

Pages